Method of Administration of Tranexamic Acid Injection
Tranexamic acid should be administered intravenously as a slow infusion at 1 mL/minute (or over 10 minutes for a 1 g dose) to avoid hypotension, with the specific dosing regimen dependent on the clinical indication.
Route of Administration
Intravenous (IV) administration is the standard and recommended route for tranexamic acid injection 1. The FDA label explicitly states "FOR INTRAVENOUS USE ONLY" and warns against incorrect routes of administration 1.
Alternative Routes (Context-Specific)
While IV is standard, research has explored other routes:
Intramuscular (IM): May be useful in pre-hospital or resource-limited settings where IV access is challenging. However, IM administration requires a doubled dose (30 mg/kg instead of 15 mg/kg) to achieve serum concentrations comparable to IV administration 2. Bioavailability is approximately 105% for IM versus IV 3.
Intra-articular/Peri-articular: Used specifically in orthopedic surgery (TKA) to reduce local bleeding, but this is a distinct application from systemic hemorrhage control 4, 5, 6.
Infusion Rate: Critical Safety Consideration
The infusion rate must not exceed 1 mL/minute to prevent hypotension 1. For a standard 1 g dose (10 mL of 100 mg/mL solution), this translates to administration over 10 minutes.
Common Pitfall
Rapid IV push or bolus administration can cause significant hypotension. Always use controlled infusion over the specified timeframe.
Indication-Specific Dosing Protocols
Post-Partum Hemorrhage (WHO Guidelines)
First dose: 1 g IV over 10 minutes (at 1 mL/min), given as soon as clinically diagnosed PPH is identified 7
Second dose: 1 g IV if bleeding continues after 30 minutes OR restarts within 24 hours of the first dose 7
Critical timing: Must be administered within 3 hours of birth—benefit decreases by 10% for every 15-minute delay, with no benefit and potential harm beyond 3 hours 7
Trauma (European Guidelines)
Loading dose: 1 g IV over 10 minutes, administered as soon as possible (ideally within 90 minutes of injury, maximum 3 hours) 8, 9
Maintenance infusion: 1 g IV over 8 hours 8
Optimal window: Recent evidence suggests maximum benefit occurs within 90 minutes of injury, with adjusted risk ratio of 0.64 (95% CI 0.50-0.82) for mortality reduction 9. Beyond 90 minutes, mortality benefit is not statistically significant.
Hemophilia/Dental Extraction
Pre-extraction: 10 mg/kg actual body weight IV with replacement therapy 1
Post-extraction: 10 mg/kg IV 3-4 times daily for 2-8 days, infused at no more than 1 mL/minute 1
Dose Adjustments
Renal Impairment
Dose reduction is required for patients with renal impairment, though specific adjustments are not detailed in the provided evidence 1. Consult full prescribing information for creatinine clearance-based dosing.
Contraindications to Administration
Absolute contraindications 1:
- Subarachnoid hemorrhage (risk of cerebral edema and infarction)
- Active intravascular clotting
- Severe hypersensitivity to tranexamic acid
Relative contraindication 7:
- Known thromboembolic event during pregnancy (for obstetric use)
Critical Safety Warning
Never administer via neuraxial route—inadvertent injection into the neuraxial system can cause seizures 1. The FDA label emphasizes this risk of medication errors due to incorrect route of administration.
Monitoring During Administration
- Monitor for hypotension during infusion (especially if rate exceeds 1 mL/min)
- Watch for hypersensitivity reactions (discontinue immediately if severe reaction occurs) 1
- Be alert for visual disturbances (discontinue if ocular symptoms develop) 1
- Advise patients about potential dizziness 1
Key Clinical Pearls
Earlier is better: For both trauma and PPH, every minute counts—benefit diminishes rapidly with delay 7, 9
Don't wait for lab results: In trauma, TXA should not await viscoelastic assessment results 8
Avoid concomitant Factor IX: Risk of thrombosis increases with concurrent use of Factor IX or other prothrombotic products 1
No evidence for oral route in acute bleeding: While oral bioavailability is 46%, this route is not recommended for acute hemorrhage control 3